VolitionRx

Executive Summary

VolitionRx is a Singapore-based biotechnology company pioneering the early detection and monitoring of life-threatening diseases through its proprietary Nucleosomics™ platform. The company's Nu.Q® suite of diagnostic tests quantifies nucleosome epigenetic signatures in blood, enabling cost-effective, CE-marked liquid biopsies for cancer, sepsis, NETosis, and veterinary cancers. By targeting the epigenome, VolitionRx offers a transformative approach to disease screening, with the potential to improve patient outcomes through earlier intervention. The company has raised $2.2 million to date and operates in the commercial stage, leveraging its validated technology to address significant unmet needs in oncology and critical care. VolitionRx's platform is differentiated by its ability to detect a broad range of cancers and inflammatory conditions from a single blood draw, supported by over a decade of research and multiple published studies. With growing demand for non-invasive diagnostic tools, the company is well-positioned to capture market share in the multi-billion-dollar liquid biopsy space. Near-term focus includes expanding clinical validation, pursuing regulatory approvals in key markets like the US, and forging strategic partnerships to accelerate commercial adoption. VolitionRx's conviction score is driven by its proven technology, commercial readiness, and large addressable market, offset by the competitive landscape and capital needs for scaling.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for Nu.Q Cancer screening test40% success
• Q1 2027Strategic partnership for Nu.Q Sepsis test commercialization50% success
• Q3 2026Publication of pivotal clinical study in a peer-reviewed journal70% success